A Pilot Study of Short-course Nivolumab and Low-dose Ipilimumab for Adjuvant Treatment of Melanoma Brown University Oncology Research Group Trial, BrUOG 324

被引：2

作者：

Constantinou, Maria ^{[1
]}

Miner, Thomas J. ^{[1
]}

Vatkevitch, John M. ^{[1
]}

Naboush, Ali ^{[1
]}

Dionson, Sopha ^{[1
]}

Anderson, Jasmine ^{[1
]}

Kolvek, Taylor ^{[1
]}

Medeiros, Maria ^{[1
]}

MacKinnon, Kelsey ^{[1
]}

Wood, Roxanne ^{[1
]}

Safran, Howard ^{[1
]}

机构：

[1] Rhode Isl Hosp, Lifespan Canc Inst, Providence, RI 02906 USA

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2021年 / 44卷 / 06期

关键词：

nivolumab; ipilimumab; adjuvant treatment; melanoma; immune checkpoint inhibitors; cutaneous oncology; immunotherapy; PD-1; inhibitors; CTLA-4; STAGE-III; PLUS IPILIMUMAB;

D O I：

10.1097/COC.0000000000000820

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Combined cytotoxic T-lymphocyte-associated antigen 4 and programmed death 1 inhibitor blockade is a promising strategy in advanced melanoma and other solid tumors. This pilot study assessed the safety and toxicity of nivolumab plus low-dose ipilimumab in patients with high-risk completely resected melanoma. Patients and Methods: Patients received ipilimumab, 1 mg/kg every 6 weeks, and nivolumab, 3 mg/kg every 2 weeks, for a total of 24 weeks (4 cycles). The primary objective was to assess the toxicity of the combined regimen. Results: Twenty-one patients with resected melanoma were enrolled. One patient was stage IIC, 16 patients were stage III and 4 patients had resected stage 4 disease. Ten of 21 (48%) had grade 3 treatment-related toxicities but there was no grade 4 or grade 5 toxicities. The rate of grade 3 nonhematologic toxicities exceeded the toxicity limits defined by the study. Fifteen of 21 patients (71%) completed all 4 cycles of therapy. The median follow-up is 41 months. The 2-year recurrence-free survival is 85.7% and the 2-year overall survival is 90.5%. Conclusion: A 6-month course of nivolumab and low-dose ipilimumab may be a promising adjuvant treatment for patients with resected melanoma. Further studies of this regimen are indicated.

引用

页码：254 / 257

页数：4

共 12 条

[1] Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy [J].

Eggermont, A. M. M. ;

Chiarion-Sileni, V. ;

Grob, J. -J. ;

Dummer, R. ;

Wolchok, J. D. ;

Schmidt, H. ;

Hamid, O. ;

Robert, C. ;

Ascierto, P. A. ;

Richards, J. M. ;

Lebbe, C. ;

Ferraresi, V. ;

Smylie, M. ;

Weber, J. S. ;

Maio, M. ;

Bastholt, L. ;

Mortier, L. ;

Thomas, L. ;

Tahir, S. ;

Hauschild, A. ;

Hassel, J. C. ;

Hodi, F. S. ;

Taitt, C. ;

de Pril, V. ;

de Schaetzen, G. ;

Suciu, S. ;

Testori, A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1845-1855

[2] Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma [J].

Eggermont, Alexander M. M. ;

Blank, Christian U. ;

Mandala, Mario ;

Long, Georgina, V ;

Atkinson, Victoria ;

Dalle, Stephane ;

Haydon, Andrew ;

Lichinitser, Mikhail ;

Khattak, Adnan ;

Carlino, Matteo S. ;

Sandhu, Shahneen ;

Larkin, James ;

Puig, Susana ;

Ascierto, Paolo A. ;

Rutkowski, Piotr ;

Schadendorf, Dirk ;

Koornstra, Rutger ;

Hernandez-Aya, Leonel ;

Maio, Michele ;

van den Eertwegh, Alfonsus J. M. ;

Grob, Jean-Jacques ;

Gutzmer, Ralf ;

Jamal, Rahima ;

Lorigan, Paul ;

Ibrahim, Nageatte ;

Marreaud, Sandrine ;

van Akkooi, Alexander C. J. ;

Suciu, Stefan ;

Robert, Caroline .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (19) :1789-1801

[3] Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer [J].

Hellmann, M. D. ;

Paz-Ares, L. ;

Bernabe Caro, R. ;

Zurawski, B. ;

Kim, S. -W. ;

Carcereny Costa, E. ;

Park, K. ;

Alexandru, A. ;

Lupinacci, L. ;

de la Mora Jimenez, E. ;

Sakai, H. ;

Albert, I. ;

Vergnenegre, A. ;

Peters, S. ;

Syrigos, K. ;

Barlesi, F. ;

Reck, M. ;

Borghaei, H. ;

Brahmer, J. R. ;

O'Byrne, K. J. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Rabindran, S. K. ;

Kasinathan, R. S. ;

Nathan, F. E. ;

Ramalingam, S. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) :2020-2031

[4]

Hellmann MD, 2017, LANCET ONCOL, V18, P31, DOI [10.1016/S1470-2045(16)30624-6, 10.1016/s1470-2045(16)30624-6]

[5] Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma [J].

Larkin, J. ;

Chiarion-Sileni, V. ;

Gonzalez, R. ;

Grob, J-J ;

Rutkowski, P. ;

Lao, C. D. ;

Cowey, C. L. ;

Schadendorf, D. ;

Wagstaff, J. ;

Dummer, R. ;

Ferrucci, P. F. ;

Smylie, M. ;

Hogg, D. ;

Hill, A. ;

Marquez-Rodas, I. ;

Haanen, J. ;

Guidoboni, M. ;

Maio, M. ;

Schoffski, P. ;

Carlino, M. S. ;

Lebbe, C. ;

McArthur, G. ;

Ascierto, P. A. ;

Daniels, G. A. ;

Long, G. V. ;

Bastholt, L. ;

Rizzo, J. I. ;

Balogh, A. ;

Moshyk, A. ;

Hodi, F. S. ;

Wolchok, J. D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (16) :1535-1546

[6] Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma [J].

Long, G. V. ;

Hauschild, A. ;

Santinami, M. ;

Atkinson, V. ;

Mandala, M. ;

Chiarion-Sileni, V. ;

Larkin, J. ;

Nyakas, M. ;

Dutriaux, C. ;

Haydon, A. ;

Robert, C. ;

Mortier, L. ;

Schachter, J. ;

Schadendorf, D. ;

Lesimple, T. ;

Plummer, R. ;

Ji, R. ;

Zhang, P. ;

Mookerjee, B. ;

Legos, J. ;

Kefford, R. ;

Dummer, R. ;

Kirkwood, J. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19) :1813-1823

[7] Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma [J].

Motzer, R. J. ;

Tannir, N. M. ;

McDermott, D. F. ;

Frontera, O. Aren ;

Melichar, B. ;

Choueiri, T. K. ;

Plimack, Elizabeth R. ;

Barthelemy, P. ;

Porta, C. ;

George, S. ;

Powles, T. ;

Donskov, F. ;

Neiman, V. ;

Kollmannsberger, C. K. ;

Salman, P. ;

Gurney, H. ;

Hawkins, R. ;

Ravaud, A. ;

Grimm, M. -O. ;

Bracarda, S. ;

Barrios, C. H. ;

Tomita, Y. ;

Castellano, D. ;

Rini, B. I. ;

Chen, A. C. ;

Mekan, S. ;

McHenry, M. B. ;

Wind-Rotolo, M. ;

Doan, J. ;

Sharma, P. ;

Hammers, H. J. ;

Escudier, B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (14) :1277-1290

[8]

Sade-Feldman M, 2018, CELL, V175, P998, DOI [10.1016/j.cell.2018.10.038, 10.1016/j.cell.2018.12.034]

[9] Systemic Immunity Is Required for Effective Cancer Immunotherapy [J].

Spitzer, Matthew H. ;

Carmi, Yaron ;

Reticker-Flynn, Nathan E. ;

Kwek, Serena S. ;

Madhireddy, Deepthi ;

Martins, Maria M. ;

Gherardini, Pier Federico ;

Prestwood, Tyler R. ;

Chabon, Jonathan ;

Bendall, Sean C. ;

Fong, Lawrence ;

Nolan, Garry P. ;

Engleman, Edgar G. .

CELL, 2017, 168 (03) :487-+

[10] Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609 [J].

Tarhini, Ahmad A. ;

Lee, Sandra J. ;

Hodi, F. Stephen ;

Rao, Uma N. M. ;

Cohen, Gary I. ;

Hamid, Omid ;

Hutchins, Laura F. ;

Sosman, Jeffrey A. ;

Kluger, Harriett M. ;

Eroglu, Zeynep ;

Koon, Henry B. ;

Lawrence, Donald P. ;

Kendra, Kari L. ;

Minor, David R. ;

Lee, Carrie B. ;

Albertini, Mark R. ;

Flaherty, Lawrence E. ;

Petrella, Teresa M. ;

Streicher, Howard ;

Sondak, Vernon K. ;

Kirkwood, John M. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06) :567-+

← 1 2 →